A Pharmacometabolomics-Based Application to Evaluate the Impact of Medical Cannabis Treatment on Children with Autism Spectrum Disorder

Time: 12:00 pm
day: Day 2 Track B - Morning


  • Examine how successful autism spectrum disorder (ASD) treatment is challenging due to subjective evaluation of changes in social interaction, language and communication ability, and repetitive behaviors, observed by clinician and family members of the individual with ASD
  • Study metabolic biomarkers and how they are an attractive method to quantify and personalize medical cannabis (MC) treatment for individuals with ASD
  • Investigate how such biomarkers also present an opportunity to understand the underlying mechanism of action (MOA) of MC treatment in individuals with ASD
  • Inspect how Cannabis-Responsive™ biomarkers in saliva provide a scientifically validated technology to objectively quantify the impact of MC and can indicate the MOA in children with ASD treated under physician supervision